

Rachel E Rau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9142524/publications.pdf>

Version: 2024-02-01

80
papers

1,817
citations

394286

19
h-index

276775

41
g-index

84
all docs

84
docs citations

84
times ranked

3450
citing authors

#	ARTICLE	IF	CITATIONS
1	DNMT3A in haematological malignancies. <i>Nature Reviews Cancer</i> , 2015, 15, 152-165.	12.8	379
2	The incidence and clinical significance of nucleophosmin mutations in childhood AML. <i>Blood</i> , 2007, 110, 979-985.	0.6	193
3	Nucleophosmin (<i>NPM1</i>) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. <i>Hematological Oncology</i> , 2009, 27, 171-181.	0.8	127
4	DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. <i>Blood</i> , 2016, 128, 971-981.	0.6	107
5	DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias. <i>Cancer Cell</i> , 2016, 29, 922-934.	7.7	107
6	Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit. <i>American Journal of Infection Control</i> , 2004, 32, 189-195.	1.1	98
7	Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Chemistry and Biology</i> , 2013, 20, 1352-1363.	6.2	72
8	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28073.	0.8	52
9	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. <i>Oncotarget</i> , 2014, 5, 8947-8958.	0.8	51
10	Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. <i>Experimental Hematology</i> , 2016, 44, 740-744.	0.2	48
11	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26873.	0.8	48
12	Fatal Infection Caused by <i>Cupriavidus gilardii</i> in a Child with Aplastic Anemia. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1005-1007.	1.8	39
13	<i>MLL</i> rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. <i>British Journal of Haematology</i> , 2013, 160, 785-797.	1.2	39
14	A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. <i>Blood</i> , 2019, 134, 1960-1972.	0.6	38
15	Triad of Severe Abdominal Pain, Inappropriate Antidiuretic Hormone Secretion, and Disseminated Varicella-Zoster Virus Infection Preceding Cutaneous Manifestations After Hematopoietic Stem Cell Transplantation. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 265-268.	1.1	37
16	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. <i>Experimental Hematology</i> , 2014, 42, 101-113.e5.	0.2	32
17	The genomics of acute myeloid leukemia in children. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 189-209.	2.7	26
18	Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	22

#	ARTICLE	IF	CITATIONS
19	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	1.2	21
20	Can recombinant technology address asparaginase <i>Erwinia chrysanthemi</i> shortages?. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29169.	0.8	18
21	A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Pediatric Blood and Cancer</i> , 2018, 65, e27066.	0.8	15
22	Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e132-e143.	1.8	15
23	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. <i>Haematologica</i> , 2022, 107, 887-898.	1.7	15
24	Use of Allopurinol to Mitigate 6-Mercaptopurine Associated Gastrointestinal Toxicity in Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 1129.	1.3	13
25	Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model. <i>Blood</i> , 2014, 124, 3572-3572.	0.6	12
26	Constitutive loss of DNMT3A causes morbid obesity through misregulation of adipogenesis. <i>ELife</i> , 0, 11, .	2.8	12
27	Prevention of mercaptopurine-induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27577.	0.8	11
28	Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26487.	0.8	10
29	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	0.6	10
30	Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28063.	0.8	9
31	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	0.8	9
32	Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27905.	0.8	7
33	Beyond KIT in CBF-AML: chromatin and cohesin. <i>Blood</i> , 2016, 127, 2370-2371.	0.6	6
34	Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. <i>Blood Advances</i> , 2021, 5, 3876-3890.	2.5	6
35	Using genomics to define pediatric blood cancers and inform practice. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 286-300.	0.9	6
36	Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. <i>Oncotarget</i> , 2018, 9, 35313-35326.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Association of race and ethnicity with clinical phenotype, genetics, and survival in pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 4992-5001.	2.5	6
38	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018, 132, 1405-1405.	0.6	5
39	Klinefelter syndrome and 47, <sc>XYY</sc> syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 843-846.	1.2	4
40	Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2018, 13, e0197408.	1.1	4
41	A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7568-TPS7568.	0.8	4
42	Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases. <i>Blood</i> , 2021, 138, 2307-2307.	0.6	4
43	Murine Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
44	CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3. <i>Blood</i> , 2017, 130, 385-386.	0.6	3
45	How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S8-S11.	0.2	3
46	An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. <i>Leukemia</i> , 2021, 35, 1777-1781.	3.3	3
47	A viral cause of APL. <i>Blood</i> , 2021, 138, 1653-1655.	0.6	3
48	Ponatinib use in two pediatric patients with relapsed Ph ϵ + α ALL with ABL1 kinase domain mutations. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 514-519.	0.3	2
49	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. <i>Blood</i> , 2015, 126, 1312-1312.	0.6	2
50	Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3789-3789.	0.6	2
51	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. <i>Blood</i> , 2018, 132, 549-549.	0.6	1
52	Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.. <i>Blood</i> , 2006, 108, 221-221.	0.6	1
53	Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. <i>Blood</i> , 2010, 116, 145-145.	0.6	1
54	Dnmt3a-Deletion Accelerates FLT3-ITD Malignancies In Mice By Hypomethylation Of Enhancer Sites and Activating Stem Cell Programs; Implications For Therapy. <i>Blood</i> , 2013, 122, 595-595.	0.6	1

#	ARTICLE	IF	CITATIONS
55	A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplasm in Double Knock-in Mice with WT1 and FLT3/ITD Mutations. <i>Blood</i> , 2015, 126, 312-312.	0.6	1
56	A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314). <i>Journal of Clinical Oncology</i> , 2016, 34, 2567-2567.	0.8	1
57	Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 7033-7033.	0.8	1
58	Efficacy and safety of intramuscular (IM) recombinant <i>Erwinia</i> asparaginase in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): The Children's Oncology Group (COG) AALL1931 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 7001-7001.	0.8	1
59	50 Years Ago in The Journal of Pediatrics. <i>Journal of Pediatrics</i> , 2017, 183, 140.	0.9	0
60	3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials. <i>Journal of Clinical and Translational Science</i> , 2019, 3, 30-31.	0.3	0
61	Measure Twice, Cut Once: Therapeutic Editing of HSPCs Requires Precise Planning. <i>Cell Stem Cell</i> , 2019, 24, 511-512.	5.2	0
62	SIRPassing other xenograft murine models?. <i>Blood</i> , 2020, 135, 1612-1614.	0.6	0
63	Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S99-S101.	0.2	0
64	Predictors of Acute Intracranial Pathology Identified by Computerized Tomography in Children with Sickle Cell Disease. <i>Blood</i> , 2006, 108, 3798-3798.	0.6	0
65	Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines. <i>Blood</i> , 2009, 114, 2742-2742.	0.6	0
66	Chemotherapy-Induced CXCR4 Modulation Predicts the In Vivo Efficacy of Plerixafor As a Chemosensitizer in Acute Leukemia. <i>Blood</i> , 2011, 118, 1410-1410.	0.6	0
67	Leukemogenic WT1 Mutations Increase Proliferation by Accelerating Cell Entry Into S-Phase, and Synergize with FLT3/ITD Mutations to Enhance These Aberrant Cell Cycle Effects. <i>Blood</i> , 2011, 118, 2437-2437.	0.6	0
68	Next-Generation NAMPT Inhibitors For ALL Identified By Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens. <i>Blood</i> , 2013, 122, 171-171.	0.6	0
69	Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis. <i>Blood</i> , 2013, 122, 1269-1269.	0.6	0
70	DOT1L As a Therapeutic Target for the Treatment of DNMT3A-Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 614-614.	0.6	0
71	Targeting BCL6-Mediated Resistance to BCR-ABL Targeted Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) through the Addition of Histone Deacetylase (HDAC) Inhibitors. <i>Blood</i> , 2015, 126, 1277-1277.	0.6	0
72	Aberrant Precursor B Lymphoid Blast Population in a Patient with Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 5557-5557.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Leukemia Fusion Gene Detection in the Clinical Molecular Laboratory Using RNA-Based Targeted Next-Generation Sequencing. <i>Blood</i> , 2016, 128, 4074-4074.	0.6	0
74	Abstract 145: Pharmacologic inhibition of SIAH2 stabilizes DYRK2 and inhibits survival and self-renewal in chronic myeloid leukemia (CML) leukemic stem cells. , 2018, , .		0
75	Mosaic DNMT3A Germline Mutation As a Model for Mutant DNMT3A Competitive Advantage in the Blood Lineage. <i>Blood</i> , 2018, 132, 173-173.	0.6	0
76	A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3792-3792.	0.6	0
77	Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in <i>Pseudomonas Fluorescens</i> (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to <i>Escherichia coli</i> -Derived Asparaginases. <i>Blood</i> , 2019, 134, 2586-2586.	0.6	0
78	Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with <i>KMT2A</i> Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 34-34.	0.6	0
79	Impact of Race/Ethnicity on Pediatric Core Binding Factor AML Outcomes and Response to Gemtuzumab Ozogamicin. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
80	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	0.8	0